LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP & OTC US: EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other malignancies with unmet medical needs, announced today that it received yesterday evening the “European Small and Mid-Cap” award in the “Most Innovative Newcomer” category by the Federation of European Stock Exchanges.
